Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Catalio Capital Management, LP 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Catalio Capital Management, LP (CIK 1958125) reported $478.7M across 37 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: DNTH ($47.0M, 9.82%), BBIO ($32.1M, 6.70%), ASND ($29.5M, 6.17%), BMY ($25.5M, 5.33%), SNDX ($24.4M, 5.09%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1DNTHDIANTHUS THERAPEUTICS INC$47.0M9.82%560,308Trimmed
2BBIOBRIDGEBIO PHARMA INC$32.1M6.70%432,014New
3ASNDASCENDIS PHARMA A/S$29.5M6.17%129,111Added
4BMYBRISTOL-MYERS SQUIBB CO$25.5M5.33%420,727Trimmed
5SNDXSYNDAX PHARMACEUTICALS INC$24.4M5.09%1.0MTrimmed
6GILDGILEAD SCIENCES INC$22.8M4.77%163,905Trimmed
7TERNTERNS PHARMACEUTICALS INC$21.6M4.50%409,031Added
8DEFINIUM THERAPEUTICS INC$19.6M4.10%1.0MNew
9SLNOSOLENO THERAPEUTICS INC$19.3M4.04%577,808Added
10BSXBOSTON SCIENTIFIC CORP$18.8M3.92%299,318Trimmed
11RAREULTRAGENYX PHARMACEUTICAL IN$17.8M3.72%850,797Added
12INCYINCYTE CORP$17.1M3.58%182,101New
13CYTKCYTOKINETICS INC$14.2M2.97%215,501Trimmed
14NTRANATERA INC$14.2M2.96%70,907Added
15CRVSCORVUS PHARMACEUTICALS INC$13.0M2.73%891,933New
16GPCRSTRUCTURE THERAPEUTICS INC$12.3M2.57%255,379Added
17MLYSMINERALYS THERAPEUTICS INC$11.9M2.48%439,041Added
18EWEDWARDS LIFESCIENCES CORP$11.6M2.42%144,607Trimmed
19VERADERMICS INC$11.0M2.29%173,582New
20ADPTADAPTIVE BIOTECHNOLOGIES COR$10.0M2.10%722,784Trimmed
21HEARTFLOW INC$9.8M2.05%403,588Added
22KALVKALVISTA PHARMACEUTICALS INC$8.6M1.79%426,551New
23QUREUNIQURE NV$8.0M1.68%491,116Added
24IRONDISC MEDICINE INC$7.9M1.64%122,978Added
25SEPNSEPTERNA INC$7.1M1.48%294,360Hold

Source: SEC Form 13F filings · as of 2026-03-31